Bernadette Connaughton Sells 829 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 829 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $71.60, for a total value of $59,356.40. Following the completion of the sale, the director directly owned 42,123 shares in the company, valued at $3,016,006.80. This trade represents a 1.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Bernadette Connaughton also recently made the following trade(s):

• On Monday, November 10th, Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $68.48, for a total value of $136,960.00.
• On Wednesday, October 1st, Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $75.24, for a total transaction of $150,480.00.
• On Tuesday, September 2nd, Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00.

Halozyme Therapeutics Price Performance

HALO traded down $3.30 during midday trading on Monday, reaching $68.10. 2,269,023 shares of the company’s stock were exchanged, compared to its average volume of 2,031,001. Halozyme Therapeutics, Inc. has a 1-year low of $46.26 and a 1-year high of $79.50. The stock has a market capitalization of $8.01 billion, a PE ratio of 15.58, a P/E/G ratio of 0.35 and a beta of 1.18. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The business’s 50-day moving average price is $69.05 and its 200 day moving average price is $64.09.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business had revenue of $354.26 million for the quarter, compared to analyst estimates of $339.18 million. During the same period in the prior year, the business earned $1.27 earnings per share. The company’s quarterly revenue was up 22.1% on a year-over-year basis. As a group, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Leerink Partners raised Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target for the company in a research report on Tuesday, October 14th. Zacks Research lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Leerink Partnrs raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 14th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. Finally, Morgan Stanley decreased their price target on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. Seven equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $75.10.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Root Financial Partners LLC acquired a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at about $25,000. Larson Financial Group LLC grew its holdings in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares during the period. Richardson Financial Services Inc. grew its holdings in Halozyme Therapeutics by 87.6% in the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 198 shares during the period. Wealth Preservation Advisors LLC acquired a new position in Halozyme Therapeutics during the first quarter worth approximately $32,000. Finally, SVB Wealth LLC purchased a new position in Halozyme Therapeutics during the first quarter worth approximately $33,000. 97.79% of the stock is owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.